Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361323 | 0.93 | CACNA1B (0.61) | CACNA1BHRH3TACR1ALDH1A1BCL2 | |
| SCHEMBL5355876 | 0.93 | CACNA1B (0.51) | CACNA1BMEN1KMT2AMCL1ACKR3 | |
| SCHEMBL5361820 | 0.92 | CACNA1B (0.51) | CACNA1BATMHSD17B10MCL1HDAC8 | |
| SCHEMBL5345730 | 0.92 | CACNA1B (0.49) | CACNA1BATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5345749 | 0.92 | CACNA1B (0.49) | CACNA1BATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5350467 | 0.92 | CACNA1B (0.49) | CACNA1BATMMEN1KMT2AALDH1A1 | |
| SCHEMBL5349400 | 0.92 | CACNA1B (0.49) | CACNA1BATMMEN1KMT2AALDH1A1 | |
| SCHEMBL4843256 | 0.91 | CACNA1B (0.57) | CACNA1BKMT2AHRH3TACR1ALDH1A1 | |
| SCHEMBL5348579 | 0.91 | CACNA1B (0.52) | CACNA1BATMHSD17B10MEN1KMT2A | |
| SCHEMBL5112745 | 0.90 | CACNA1B (0.47) | CACNA1BATMHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | claimed |
| EP-0997147-B1 | AMINO ACID DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2006-03-15 | — | — | EP | claimed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | claimed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-0997147-B1 | AMINO ACID DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6903119-B1 | Amino acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
| EP-1097929-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1B, CACNA1A | CACNA1B 2/4885ATM 2523/4885HSD17B10 4740/4885 |
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | CACNA1B 1/4885ATM 3517/4885HSD17B10 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.